Biologically created drugs are the biggest cost for public health plans like B.C. Pharmacare. (Flickr)

B.C. Pharmacare expanding use of ‘biosimilar’ drugs to save money

Europe far ahead of Canada in adopting alternative treatments

Bioengineered drugs for conditions such as diabetes and arthritis are the most expensive part of B.C.’s Pharmacare and other public drug plans, and new alternatives are being introduced.

The shift began Monday with the introduction of a diabetes drug called Jardiance, and a psoriatic arthritis drug called Talz. Coverage is also enhanced for arthritis treatments including certolizumab, leflunomide, rituximab, tocilizumab and tofacitinab.

A list of affected drug treatments can be found here.

The change is expected to save the province $96 million over the first three years, Health Minister Adrian Dix said. B.C. is following the lead of Europe in moving to alternative drugs, replacing patented treatments made from biological sources such as yeasts.

Medical experts say “biosimilars” are genetically as identical as these types of drugs can be. Affected patients in B.C. will be given a six-month transition period with their doctors to introduce the alternative treatments and identify exceptions.

“Biosimilars are a necessary step to ensure Pharmacare coverage provides existing coverage for more people and fund new drugs well into the future,” Dix said.

Cheryl Koehn, president of Arthritis Consumer Experts who has been living with rheumatoid arthritis for decades, said she works with people struggling to get reimbursement for medications recommended by their rheumatologists.

“Today’s announcement is a direct answer to this problem, clinically and financially,” Koehn said. “It ensures continued reimbursement coverage for British Columbians who transition to the next-generation biologic and ensures that reimbursement for other patents becomes available.”

Dr. Tom Elliott, medical director of B.C. Diabetes, said extending coverage for Jardiance for Type 2 diabetes is financed by savings from using insulin glargine biosimilar Basaglar in place of the biologic Lantus.

“This change will entail some inconvenience and require some adaptation for the tens of thousands of British Columbians currently using Lantus and their prescribing physicians,” Elliott said. “Patients and prescribers can rest assured that Basaglar has the same effectiveness and time release pattern, unit for unit, as Lantus.”


@tomfletcherbc
tfletcher@blackpress.ca

Like us on Facebook and follow us on Twitter.

Just Posted

Nine fires burning in West Kootenay

All fires considered to be lightning caused.

Castlegar mayor releases FCM itinerary

Bruno Tassone delivers promised report on activities at Quebec City municipal conference

West Kootenay afternoon storms spark fires

Lots of thunder and lightning, and little rain, as system moves through region

Rainbow Road

Nakusp cuts ribbon on rainbow crosswalk

Nakusp cops warn of firebug

Call for assistance to stop person before a major fire starts

10 facts about Father’s Day

Did you know that the special day for dads was first celebrated in 1910?

Bombers down B.C. Lions 33-23 in season opener

Former Lion Andrew Harris leads Winnipeg with 148 rushing yards

Northern B.C. family remembers murdered Indigenous woman with memorial walk

Still no closure for Ramona Wilson’s family 25 years later

B.C. university to offer mentorship program for former youth in care

Students using the provincial tuition waiver program will soon be able to form a community at KPU

You might not know these B.C. records are public

Hired a lawyer to file a civil claim? Those are published online

B.C. bus driver loses case to get job back after texting while driving full bus

An arbitator ruled that Tim Wesman’s phone usage was a “a reckless disregard for public safety”

Revamped B.C. Lions set to battle veteran Winnipeg Blue Bombers

The Lions’ first test of the season will be a big one

No business case for Trans Mountain expansion, says former environment minister

Cabinet is expected to announce its decision on the expansion of the Alberta-to-B.C. pipeline by Tuesday

LETTER: British Columbia’s forest industry crisis being made worse

Andrew Wilkinson warns of regulatory overload by John Horgan’s NDP

Most Read